SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

	(Amendment No. 3)*	
	Adaptimmune Therapeutics PLC	
	(Name of Issuer)	
	Ordinary Shares, par value GBP 0.001 per share	
	(Title of Class of Securities)	
	00653A107	
	(CUSIP Number)	
	09/30/2025 (Date of Event Which Requires Filing of this Statement)	
	(Date of Event Which Requires Filing of this Statement)	
	e appropriate box to designate the rule pursuant to which this Schedule is filed:	
Rule	13d-1(b)	
Rule	13d-1(c)	
Rule	13d-1(d)	
	SCHEDULE 13G	
CUSIP N	No. 00653A107	
-		
	Names of Reporting Persons	
1	Two Seas Capital LP	
	Check the appropriate box if a member of a Group (see instructions)	
2	□ (a)	
	(b)	
3	Sec Use Only	
	Citizenship or Place of Organization	

DELAWARE

Number of Shares Benefici ally Owned	5	Sole Voting Power		
	3	0.00		
	6	Shared Voting Power		
		0.00		
by Each Reporti	7	Sole Dispositive Power		
ng Person	,	0.00		
With:	8	Shared Dispositive Power		
		0.00		
9	Aggregate Amount Beneficially Owned by Each Reporting Person			
9	0.00			
40	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)			
10				
44	Percent of class represented by amount in row (9)			
11	0 %			
40	Type of Reporting Person (See Instructions)			
12	IA, PN			

SCHEDULE 13G

No. 00653A107

1	Names of Reporting Persons		
	Two Seas Capital GP LLC		
2	Check the appropriate box if a member of a Group (see instructions)		
	(a) (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization		
4	DELAWARE		
	5	Sole Voting Power	
Number		0.00	
of Shares	6	Shared Voting Power	
Benefici ally		0.00	
Owned by Each Reporti	7	Sole Dispositive Power	
ng Person		0.00	
With:	8	Shared Dispositive Power	
		0.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person		
	0.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)		

11	Percent of class represented by amount in row (9)
	0 %
40	Type of Reporting Person (See Instructions)
12	OO, HC

SCHEDULE 13G

CUSIP No.	00653A107
-----------	-----------

Names of Reporting Persons				
Sina Toussi				
Check the appropriate box if a member of a Group (see instructions)				
(a) (b)				
Sec Use Only				
Citizenship or Place of Organization				
UNITED STATES				
5	Sole Voting Power			
	0.00			
6	Shared Voting Power			
6	0.00			
7	Sole Dispositive Power			
	0.00			
8	Shared Dispositive Power			
0	0.00			
Aggregate Amount Beneficially Owned by Each Reporting Person				
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)				
Percent of class represented by amount in row (9)				
Type of Reporting Person (See Instructions)				
IN, HC				
	Check the (a) (b) Sec Use (Citizensh UNITED S) 6 7 8 Aggregat 0.00 Check bot (Check bot (Chec			

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Adaptimmune Therapeutics PLC

(b) Address of issuer's principal executive offices:

60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, United Kingdom, OX14 4RX

Item 2.

(a) Name of person filing:

The Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons")

(i) Two Seas Capital LP ("TSC"); (ii) Two Seas Capital GP LLC ("TSC GP"); and

(iii) Sina Toussi.

This statement relates to Ordinary Shares, par value GBP 0.001 per share (the "Shares"), of Adaptimmune Therapeutics plc (the "Issuer") previously held by Two Seas Global (Master) Fund LP (the "Global Fund"). The principal business of TSC is providing investment advice as a registered investment adviser and serving as investment manager to the Global Fund. As such, TSC has been granted investment discretion over portfolio investments, including the Shares, previously held by or for the account of the Global Fund, including the Global Fund's voting and discretionary decisions. TSC GP serves as general partner of TSC. Sina Toussi serves as the chief investment officer of TSC and managing member of TSC GP.

(b) Address or principal business office or, if none, residence:

The address of the principal business office of each of the Reporting Persons is 32 Elm Place - 3rd Floor, Rye, New York 10580.

(c) Citizenship:

- (i) Two Seas Capital LP is a Delaware limited partnership; (ii) Two Seas Capital GP LLC is a Delaware limited liability company; and
- (iii) Sina Toussi is a United States citizen.
- (d) Title of class of securities:

Ordinary Shares, par value GBP 0.001 per share

(e) **CUSIP No.:**

00653A107

- Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
 - (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
 - (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
 - Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (c)
 - (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
 - An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); (e)
 - An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); (f)
 - A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); (g)
 - A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (h)
 - A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment (i) Company Act of 1940 (15 U.S.C. 80a-3);
 - A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § (j) 240.13d-1(b)(1)(ii)(J),

please specify the type of institution:

(k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned: (a)

As of September 30, 2025, each of the Reporting Persons did not beneficially own any Shares.

(b) Percent of class:

As of September 30, 2025, each of the Reporting Persons owned 0% of the Issuer's outstanding Shares. %

- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote:

As of September 30, 2025, the Reporting Persons had sole power to vote or to direct the vote of 0 Shares.

(ii) Shared power to vote or to direct the vote:

As of September 30, 2025, the Reporting Persons had shared power to vote or to direct the vote of 0 Shares.

(iii) Sole power to dispose or to direct the disposition of:

As of September 30, 2025, the Reporting Persons had sole power to dispose or to direct the disposition of 0 Shares.

(iv) Shared power to dispose or to direct the disposition of:

As of September 30, 2025, the Reporting Persons had shared power to dispose or to direct the disposition of 0 Shares.

Item 5. Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

See disclosure in Item 2, which is incorporated by reference herein.

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Two Seas Capital LP

Signature: /s/ Sina Toussi

Name/Title: Sina Toussi / Managing Member of Two Seas Capital

GP LLC, its General Partner

Date: 11/14/2025

Two Seas Capital GP LLC

Signature: /s/ Sina Toussi

Name/Title: Sina Toussi / Managing Member

Date: 11/14/2025

Sina Toussi

Signature: /s/ Sina Toussi
Name/Title: Sina Toussi / Self

Date: 11/14/2025